AVIR Earnings & Financial Statements
Atea Pharmaceuticals, Inc.
$4.66
+$0.03(+0.65%)
38
Overall
60
Value
20
Tech
34
Quality
Market Cap
$371.35M
Volume
72.65K
52W Range
$2.87 - $6.45
Target Price
$8.50
AVIR earnings and financial statements: Atea Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AVIR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | $351.37M |
| Operating income | -$180.89M | -$192.95M | -$164.16M | -$130.65M | $138.38M |
| EBITDA | -$164.09M | -$167.04M | -$134.52M | -$130.39M | $138.41M |
| Net income | -$158.35M | -$168.38M | -$135.96M | -$115.91M | $121.19M |
| EPS (diluted) | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.37 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $315.22M | $464.67M | $594.97M | $666.71M | $772.89M |
| Total liabilities | $39.78M | $25.80M | $39.78M | $26.14M | $62.81M |
| Shareholders’ equity | $275.43M | $438.87M | $555.19M | $640.57M | $710.08M |
| Cash and equivalents | $95.71M | $64.70M | $143.82M | $188.46M | $764.38M |
| Long-term debt | - | $842.0K | $1.64M | $2.40M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$132.03M | -$135.50M | -$85.39M | -$120.98M | -$87.00M |
| Capital expenditure | - | - | - | -$1.94M | -$4.0K |
| Free cash flow | -$132.03M | -$135.50M | -$85.39M | -$122.92M | -$87.01M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AVIR | $4.66 | +0.6% | 72.65K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Atea Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW